Meeting
2023 ASCO Genitourinary Cancers Symposium
A prospective phase II trial of neoadjuvant sintilimab in muscle-invasive urothelial carcinoma of bladder.
Authors
Fangning Wan
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Fangning Wan , Chengyuan Gu , Chunguang Ma , Yiping Zhu , Yijun Shen , Dingwei Ye
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
ChiCTR2000032730
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 509)
DOI
10.1200/JCO.2023.41.6_suppl.509
Abstract #
509
Poster Bd #
K13
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim analysis of the ATEZOBLADDERPRESERVE phase II trial (SOGUG-2017-A-IEC(VEJ)-4).
First Author: Sergio Vazquez-Estevez
Poster
2024 ASCO Genitourinary Cancers Symposium
Tislelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for lymph node‐positive bladder cancer: Results of a prospective study.
First Author: Xiao Yang
Poster
2023 ASCO Annual Meeting
Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.
First Author: Thomas W. Flaig
Poster
2023 ASCO Annual Meeting
ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC).
First Author: Hailiang Zhang